RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) – Pipeline Review, H2 2016’, provides in depth analysis on RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted pipeline therapeutics.

The report provides comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)

The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics and enlists all their major and minor projects

The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Almac Discovery Limited

ArQule, Inc.

AstraZeneca Plc

Bayer AG

Critical Outcome Technologies Inc.

Merck & Co., Inc.

Novartis AG

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) Overview 7

Therapeutics Development 8

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Products under Development by Stage of Development 8

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Products under Development by Therapy Area 9

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Products under Development by Indication 10

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Pipeline Products Glance 12

Late Stage Products 12

Early Stage Products 13

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Products under Development by Companies 14

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Therapeutics Assessment 19

Assessment by Monotherapy/Combination Products 19

Assessment by Mechanism of Action 20

Assessment by Route of Administration 21

Assessment by Molecule Type 22

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Companies Involved in Therapeutics Development 23

Almac Discovery Limited 23

ArQule, Inc. 24

AstraZeneca Plc 25

Bayer AG 26

Critical Outcome Technologies Inc. 27

Merck & Co., Inc. 28

Novartis AG 30

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Drug Profiles 31

ADC-0008830 - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

ALM-301 - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

ARQ-092 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

AZD-5363 - Drug Profile 36

Product Description 36

Mechanism Of Action 36

R&D Progress 36

BAY-1001931 - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

BAY-1125976 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

COTI-2 - Drug Profile 41

Product Description 41

Mechanism Of Action 41

R&D Progress 41

MK-2206 - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

MK-2206 + selumetinib sulfate - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules to Inhibit Akt1/2 for Oncology - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

trametinib dimethyl sulfoxide + uprosertib - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

uprosertib - Drug Profile 56

Product Description 56

Mechanism Of Action 56

R&D Progress 56

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Dormant Projects 57

RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC

2.7.11.1) - Featured News & Press Releases 60

Jun 06, 2016: Critical Outcome Activates Second Clinical Trial Site for Its COTI-2 Gynecological Cancer Study 60

May 24, 2016: Critical Outcome Receives Additional Patent Protection for Potential Transformational P53 Cancer Treatment 60

Apr 27, 2016: Critical Outcome Technologies Augments Advisory Board Drug Development Experience 61

Apr 19, 2016: Critical Outcome Commences Treatment of Second Cohort in Phase 1 Study of COTI-2 in Gynecologic Cancers 61

Feb 16, 2016: Critical Outcome Treats First Patient in Phase 1 Study of COTI-2 in Gynecologic Cancers 62

Jan 28, 2016: ArQule Provides Update on ARQ 092 62

Dec 02, 2015: Critical Outcome Technologies Pursues Orphan Drug Designation for COTI-2 Intended to Treat Li-Fraumeni Syndrome 63

Nov 17, 2015: ArQule and the National Human Genome Research Institute of the National Institutes of Health Announce Enrollment of First Patient in the Phase 1 Proteus Syndrome Trial With ARQ 092 64

Nov 08, 2015: BIND Presents Data on MK-2206, at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 65

Oct 26, 2015: BIND Therapeutics' Presentation at Upcoming AACR-NCI-EORTC Conference Reinforce Potential of Accurin Platform to Develop Best-in-Class Therapeutics 66

Oct 15, 2015: ArQule Announces Publication of Manuscript Highlighting Activity of AKT Inhibitor ARQ 092 in Oncology 66

Sep 28, 2015: ArQule Presents Results From Phase 1b Expansion Study of ARQ 092 at the 2015 European Cancer Conference 67

May 26, 2015: FDA Grants IND to Critical Outcome Technologies for COTI-2, the Company's Activator of Mutant p53 Protein 67

May 11, 2015: Critical Outcome Technologies Adds First European Patent to Growing Intellectual Property Protection for COTI-2 68

Apr 27, 2015: Critical Outcome Technologies Files Investigational New Drug Application With the FDA for COTI-2 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Indication, H2 2016 10

Comparative Analysis by Late Stage Development, H2 2016 12

Comparative Analysis by Early Stage Products, H2 2016 13

Number of Products under Development by Companies, H2 2016 14

Products under Development by Companies, H2 2016 15

Products under Development by Companies, H2 2016 (Contd..1) 16

Products under Development by Companies, H2 2016 (Contd..2) 17

Products under Development by Companies, H2 2016 (Contd..3) 18

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Action, H2 2016 20

Number of Products by Stage and Route of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

Pipeline by Almac Discovery Limited, H2 2016 23

Pipeline by ArQule, Inc., H2 2016 24

Pipeline by AstraZeneca Plc, H2 2016 25

Pipeline by Bayer AG, H2 2016 26

Pipeline by Critical Outcome Technologies Inc., H2 2016 27

Pipeline by Merck & Co., Inc., H2 2016 28

Pipeline by Novartis AG, H2 2016 30

Dormant Projects, H2 2016 57

Dormant Projects (Contd..1), H2 2016 58

Dormant Projects (Contd..2), H2 2016 59

List of Figures

List of Figures

Number of Products under Development for, H2 2016 8

Number of Products under Development by Therapy Area, H2 2016 9

Number of Products under Development by Top 10 Indication, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 19

Number of Products by Stage and Mechanism of Actions, H2 2016 20

Number of Products by Stage and Routes of Administration, H2 2016 21

Number of Products by Stage and Molecule Type, H2 2016 22

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports